<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016250</url>
  </required_header>
  <id_info>
    <org_study_id>00-139</org_study_id>
    <secondary_id>CDR0000068613</secondary_id>
    <secondary_id>ROCHE-16113</secondary_id>
    <secondary_id>ROCHE-RO31-7453</secondary_id>
    <secondary_id>NCI-G01-1945</secondary_id>
    <nct_id>NCT00016250</nct_id>
  </id_info>
  <brief_title>Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Two Shcedules of Ro 31-7453 in Patients With Metastatic (Dukes' D) Colorectal Carcinoma (CRC) Who Have Failed Both Fluoropyrimidine and Irinotecan Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of two different regimens of&#xD;
      Ro 31-7453 in treating patients who have recurrent or refractory metastatic colorectal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the objective disease rate of patients with recurrent or refractory metastatic&#xD;
           colorectal cancer treated with two dose schedules of Ro 31-7453.&#xD;
&#xD;
        -  Compare the safety and tolerability of these regimens in these patients.&#xD;
&#xD;
        -  Compare the response duration in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the time to progression and time to treatment failure in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Determine the pharmacokinetic profiles of Ro 31-7453 and its major metabolites in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open label, multicenter study. Patients are randomized to one&#xD;
      of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral Ro 31-7453 twice daily on days 1-4. Treatment repeats every&#xD;
           21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive oral Ro 31-7453 twice daily on days 1-14. Treatment repeats&#xD;
           every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 28 days and then every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 160 patients (49 per treatment arm plus 61 additional&#xD;
      patients in the arm determined to be most effective) will be accrued for this study within 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MKC-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  At least 2.0 x 2.0 cm&#xD;
&#xD;
          -  Failed prior fluoropyrimidine and irinotecan chemotherapy in adjuvant or metastatic&#xD;
             setting&#xD;
&#xD;
               -  Must have had disease progression while receiving chemotherapy OR&#xD;
&#xD;
               -  If received fluorouracil with or without irinotecan in adjuvant setting, must&#xD;
                  also have failed therapy with these agents in metastatic setting (unless&#xD;
                  manifesting metastatic disease during adjuvant therapy)&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 ULN (5 times ULN if bone or liver metastases&#xD;
             present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No bowel obstruction&#xD;
&#xD;
          -  No active uncontrolled malabsorption syndrome&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except carcinoma in situ of the&#xD;
             cervix or non-melanoma skin cancer&#xD;
&#xD;
          -  No other active cancers, including stable disease on adjuvant therapy&#xD;
&#xD;
          -  No other medical condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior cytotoxic chemotherapy regimens for metastatic disease&#xD;
&#xD;
          -  Monoclonal antibody (MOAB) therapy and antiangiogenic agents not included as prior&#xD;
             cytotoxic chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No prior total gastrectomy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Sharma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>October 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

